Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Falutz J, Allas S, Mamputu JC, et al. AIDS 2008;22:1719-1728.
What it found
Side effect rates in the extension were similar to the first 26 weeks, and glucose changes over 52 weeks were not clinically significant. Visceral fat stayed about 18% below baseline with 52 weeks of treatment, and triglycerides fell by 51 mg/dl. Visceral fat came back in people switched to placebo.
Limitations
Extension of the first phase 3 trial (Falutz 2007); n is the number entering the extension. Only people with HIV. Effects did not last after stopping.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.